These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6831503)

  • 21. [Fenofibrate 250 SR Pharmavit in patients with mixed hyperlipoproteinemia. Results of a study of 189 patients from 13 centers in the Czech Republic].
    Ceska R; Stulc T
    Cas Lek Cesk; 2000 Jun; 139(12):369-73. PubMed ID: 10953407
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Evaluation of the effectiveness of procetofen in the treatment of hypercholesterolemia].
    Kulejewski L; Giec L
    Wiad Lek; 1985 Oct; 38(20):1409-13. PubMed ID: 3913152
    [No Abstract]   [Full Text] [Related]  

  • 24. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypolipidemic effects of bezafibrate: studies in Italy.
    Postiglione A; Riccardi G; Saldalamacchia G
    Monogr Atheroscler; 1986; 14():198-202. PubMed ID: 3526125
    [No Abstract]   [Full Text] [Related]  

  • 26. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [level of 7alpha-hydroxycholesterol in blood plasma as an indicator of cholesterol catabolism in hyperlipidemia and with hypolipidemic therapy].
    Poliakova ED; Ivanova TN; Voshchinnikov EI; Olfer'ev AM; Perova NV
    Vopr Med Khim; 2000; 46(2):168-75. PubMed ID: 10885038
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapy with fibrates and vitamin D metabolism].
    Wilczek H; Sobra J; Ceska R; Justová V; Procházková R; Kvasilová M; Jůzová Z
    Cas Lek Cesk; 1993 Oct; 132(20):630-2. PubMed ID: 8269466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [On the article by Dr. R. Ceska, et al: Fenofibrat Pharmavit SR 250 in patients with mixed hyperlipoproteinemia].
    Mayer O
    Cas Lek Cesk; 2001 Mar; 140(6):188-9. PubMed ID: 11347210
    [No Abstract]   [Full Text] [Related]  

  • 30. [Single-blind study of the efficacy of pirozadil versus alufibrate in the treatment of primary hyperlipoproteinemias].
    Honorato Pérez J; Azanza Perea JR
    Rev Med Univ Navarra; 1982 Mar; 26(1):51-4. PubMed ID: 7111953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of procetofen (lipanthyl) in hyperlipidemias (author's transl)].
    Stähelin HB; Seiler W; Pult N
    Schweiz Rundsch Med Prax; 1979 Jan; 68(1):24-8. PubMed ID: 760103
    [No Abstract]   [Full Text] [Related]  

  • 32. [Total and lipid-bound sialic acids in the blood in primary and secondary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Lupanov VP; Liakishev AA; Titov VN
    Ter Arkh; 1997; 69(1):23-5. PubMed ID: 9163043
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].
    Zvenigorodskaia LA; Mel'nikova NV; Bondarenko EIu
    Eksp Klin Gastroenterol; 2007; (1):41-6. PubMed ID: 17547112
    [No Abstract]   [Full Text] [Related]  

  • 34. [Drug therapy of hyperlipoproteinemia].
    Steinmetz A; Kaffarnik H
    Internist (Berl); 1992 Jan; 33(1):44-53. PubMed ID: 1551763
    [No Abstract]   [Full Text] [Related]  

  • 35. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Lipanor treatment of atherogenic hyperlipoproteinemia].
    Susekov AV; Tvorogova MG; Arabidze GG; Kukharchuk VV
    Ter Arkh; 1998; 70(9):57-61. PubMed ID: 9821228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The effect of micronized fenofibrate on lipid parameters and fibrinogen in heterozygous familial hypercholesterolemia and familial combined hyperlipidemia].
    Ceska R; Sobra J; Kvasnicka J; Procházková R; Kvasilová M; Haas T
    Cas Lek Cesk; 1996 Jul; 135(13):413-6. PubMed ID: 8925538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Hyperlipoproteinemia in patients with uric arthritis. The effect of treatment on the disease].
    Pavelka K; Ceska R; Sobra J; Alusík S
    Cas Lek Cesk; 1988 Mar; 127(13):394-7. PubMed ID: 3365741
    [No Abstract]   [Full Text] [Related]  

  • 39. [Fatty acid composition of phosphatidylcholine and levels of lipids and lipoproteins in hyperlipoproteinemia. I. Relation to HDL lipoprotein].
    Zák A; Zeman M; Tvrzická E
    Cas Lek Cesk; 1998 Jun; 137(12):368-71. PubMed ID: 9721473
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hyperlipoproteinemia in patients hospitalized for ischemic coronary disease and myocardial infarct].
    Cisarik F; Gavalec M; Zánová J; Hrbánová Z
    Vnitr Lek; 1981 Feb; 27(2):137-41. PubMed ID: 7467156
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.